Abstract: The process for depolymerizing Group B Types II and III Streptococcus is disclosed which results in polysaccharide fragments having a reducing end suitable for conjugating to protein. Conjugate molecules, vaccines and their use to immunize mammals including humans are also disclosed.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
September 4, 2001
Assignee:
North American Vaccine, Inc.
Inventors:
Francis Michon, Catherine Dong, Joseph Y. Tai
Abstract: This invention relates to modified pneumolysin polypeptides that retain the immunogenic nature of pneumolysin but have reduced or undetectable hemolytic activity compared to native pneumolysin. The invention also provides a method for generating novel pneumolysin variants with these desired characteristic properties. The invention also provides immunogenic compositions useful as pharmaceutical compositions including vaccines in which non-toxic, modified pneumolysin is used to stimulate protective immunity against Streptococcus pneumoniae. The vaccines may be compositions in which the modified pneumolysin is conjugated to bacterial polysaccharides or may be carried on an attenuated viral vector.
Type:
Application
Filed:
July 21, 1998
Publication date:
August 16, 2001
Applicant:
NORTH AMERICAN VACCINE, INC.
Inventors:
CONCEICAO MINETTI, FRANCIS MICHON, JEFFREY K. PULLEN, MARYELLEN POLVINO-BODNAR, SHU-MEI LIANG, JOSEPH Y. TAI
Abstract: The present invention relates, in general, to a method of expressing the outer membrane protein P2 from Haemophilus influenzae type b (Hib-P2) and fusion proteins thereof. In particular, the present invention relates to a method of expressing the outer membrane protein P2 from Haemophilus influenzae type b or fusion protein thereof in E. coli wherein the Hib-P2 protein or fusion protein comprises more than 2% of the total protein expressed in E. coli. The invention also relates to a method of purification and refolding of Hib-P2 protein and fusion protein thereof.
Type:
Grant
Filed:
July 23, 1993
Date of Patent:
November 28, 2000
Assignee:
North American Vaccine, Inc.
Inventors:
Joseph Y. Tai, Jeffrey K. Pullen, Thomas Soper, Shu-Mei Liang, Milan S. Blake
Abstract: The present invention relates, in general, to a method for the high level expression of the outer membrane protein meningococcal group B porin proteins and fusion proteins thereof. In particular, the present invention relates to a method of expressing the outer membrane protein meningococcal group B porin proteins in E. coli wherein the meningococcal group B porin proteins and fusion proteins thereof comprise more than 2% of the total protein expressed in E. coli. The invention also relates to a method of purification and refolding of the meningococcal group B porin proteins and fusion proteins thereof and to their use in vaccines.
Type:
Grant
Filed:
February 11, 1997
Date of Patent:
January 11, 2000
Assignees:
North American Vaccine, Inc., The Rockefeller University
Inventors:
Milan S. Blake, Joseph Y. Tai, Huilin L. Qi, Shu-Mei Liang, Lucjan J.J. Hronowski, Jeffrey K. Pullen
Abstract: The present invention relates, in general, to a method for the high level expression of the outer membrane protein meningococcal group B porin proteins and fusion proteins thereof. In particular, the present invention relates to a method of expressing the outer membrane protein meningococcal group B porin proteins in E. coli wherein the meningococcal group B porin proteins and fusion proteins thereof comprise more than 2% of the total protein expressed in E. coli. The invention also relates to a method of purification and refolding of the meningococcal group B porin proteins and fusion proteins thereof and to their use in vaccines.
Type:
Grant
Filed:
May 8, 1997
Date of Patent:
March 9, 1999
Assignees:
North American Vaccine, Inc., The Rockefeller University
Inventors:
Milan S. Blake, Joseph Y. Tai, Huilin L. Qi, Shu-Mei Liang, Lucjan J. J. Hronowski, Jeffrey K. Pullen
Abstract: This invention provides a novel immunogenic composition and vaccine, processes for producing them and methods for immunization against infections and disease caused by group A Streptococci. The compositions include group A streptococcal polysaccharide covalently linked to protein or liposomes to form immunogenic conjugates. The method of immunization for this invention comprises administering to an individual an immunogenic amount of group A polysaccharide. The group A polysaccharide may be administered as a vaccine either on its own, conjugated to proteins or conjugated to liposomes. Additionally, the group A polysaccharides may be associated with an adjuvant. This invention is particularly useful for providing both active and passive immunogenic protection for those populations most at risk of contracting group A Streptococcal infections and disease namely adults, pregnant women and in particular infants and children.
Type:
Grant
Filed:
April 21, 1994
Date of Patent:
February 2, 1999
Assignees:
North American Vaccine, Inc., The Rockefeller University
Inventors:
Milan S. Blake, John B. Zabriskie, Joseph Y. Tai, Francis Michon
Abstract: The present invention relates, in general, to a method for the high level expression of the outer membrane protein meningococcal group B porin proteins and fusion proteins thereof. In particular, the present invention relates to a method of expressing the outer membrane protein meningococcal group B porin proteins in E. coli wherein the meningococcal group B porin proteins and fusion proteins thereof comprise more than 2% of the total protein expressed in E. coli. The invention also relates to a method of purification and refolding of the meningococcal group B porin proteins and fusion proteins thereof and to their use in vaccines.
Type:
Grant
Filed:
June 17, 1997
Date of Patent:
May 5, 1998
Assignees:
North American Vaccine, Inc., The Rockefeller University
Inventors:
Milan S. Blake, Joseph Y. Tai, Huilin L. Qi, Shu-Mei Liang, Lucjan J. J. Hronowski, Jeffrey K. Pullen
Abstract: The present invention relates, in general, to a method for the high level expression of the outer membrane protein meningococcal group B porin proteins and fusion proteins thereof. In particular, the present invention relates to a method of expressing the outer membrane protein meningococcal group B porin proteins in E. coli wherein the meningococcal group B porin proteins yard fusion proteins thereof comprise more than 2% of the total protein expressed in E. coli. The invention also relates to a method of purification and refolding of the meningococcal group B porin proteins and fusion proteins thereof and to their use in vaccines.
Type:
Grant
Filed:
July 23, 1993
Date of Patent:
August 8, 1995
Assignees:
North American Vaccine, Inc., The Rockefeller University
Inventors:
Milan S. Blake, Joseph Y. Tai, Huilin L. Qi, Shu-Mei Liang, Lucjan J. J. Hronowski, Jeffrey K. Pullen
Abstract: An immunogenic conjugate comprising a modified group C meningococcal polysaccharide (GCMP) coupled to a carrier molecule. The GCMP is modified by O-deacetylation to a varying extent. This modified GCMP conjugate stimulates a strong immunogenic response. The antiserum, produced by immunization with this conjugate, is cross-reactive with the native polysaccharide. In addition, these antisera elicit a class of antibodies that have patent bactericidal activity.
Type:
Grant
Filed:
August 31, 1992
Date of Patent:
June 20, 1995
Assignee:
North American Vaccine, Inc.
Inventors:
Joseph Y. Tai, Lucjan J. J. Hronowski, Sharon Mates